Morgan Stanley’s AC Immune ACIU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $314K | Buy |
131,815
+42,562
| +48% | +$117K | ﹤0.01% | 5760 |
|
|
2026
Q1 | $245K | Sell |
89,253
-5,092
| -5% | -$15.8K | ﹤0.01% | 5793 |
|
|
2025
Q4 | $296K | Buy |
94,345
+2,312
| +3% | +$7.29K | ﹤0.01% | 5759 |
|
|
2025
Q3 | $266K | Buy |
92,033
+19,138
| +26% | +$43.2K | ﹤0.01% | 5772 |
|
|
2025
Q2 | $148K | Buy |
72,895
+891
| +1% | +$1.55K | ﹤0.01% | 5972 |
|
|
2025
Q1 | $135K | Sell |
72,004
-94,551
| -57% | -$238K | ﹤0.01% | 5884 |
|
|
2024
Q4 | $450K | Buy |
166,555
+101,614
| +156% | +$317K | ﹤0.01% | 5468 |
|
|
2024
Q3 | $245K | Sell |
64,941
-13,726
| -17% | -$47.9K | ﹤0.01% | 5675 |
|
|
2024
Q2 | $314K | Sell |
78,667
-1,305,187
| -94% | -$4.32M | ﹤0.01% | 5488 |
|
|
2024
Q1 | $4.1M | Sell |
1,383,854
-2,130,626
| -61% | -$7.64M | ﹤0.01% | 4072 |
|
|
2023
Q4 | $17.6M | Buy |
3,514,480
+1,772,803
| +102% | +$5.7M | ﹤0.01% | 3457 |
|
|
2023
Q3 | $4.96M | Sell |
1,741,677
-16,364
| -0.9% | -$49.8K | ﹤0.01% | 3745 |
|
|
2023
Q2 | $5.2M | Sell |
1,758,041
-192,581
| -10% | -$420K | ﹤0.01% | 3748 |
|
|
2023
Q1 | $4.56M | Hold |
1,950,622
| – | – | ﹤0.01% | 3854 |
|
|
2022
Q4 | $3.98M | Sell |
1,950,622
-26,730
| -1% | -$68.9K | ﹤0.01% | 3951 |
|
|
2022
Q3 | $6.25M | Buy |
1,977,352
+8,168
| +0.4% | +$25.7K | ﹤0.01% | 3479 |
|
|
2022
Q2 | $7.11M | Sell |
1,969,184
-35,288
| -2% | -$121K | ﹤0.01% | 3429 |
|
|
2022
Q1 | $8.02M | Sell |
2,004,472
-238,992
| -11% | -$1.03M | ﹤0.01% | 3169 |
|
|
2021
Q4 | $11.1M | Buy |
2,243,464
+1,687,761
| +304% | +$9.81M | ﹤0.01% | 2840 |
|
|
2021
Q3 | $3.73M | Buy |
555,703
+287,768
| +107% | +$2.06M | ﹤0.01% | 4027 |
|
|
2021
Q2 | $2.12M | Buy |
267,935
+185,128
| +224% | +$1.28M | ﹤0.01% | 4585 |
|
|
2021
Q1 | $630K | Sell |
82,807
-75,418
| -48% | -$539K | ﹤0.01% | 5028 |
|
|
2020
Q4 | $818K | Buy |
158,225
+13,668
| +9% | +$69.7K | ﹤0.01% | 4776 |
|
|
2020
Q3 | $706K | Buy |
144,557
+68,300
| +90% | +$490K | ﹤0.01% | 4445 |
|
|
2020
Q2 | $513K | Buy |
76,257
+5,015
| +7% | +$36.4K | ﹤0.01% | 4578 |
|
|
2020
Q1 | $492K | Sell |
71,242
-2,923
| -4% | -$22.8K | ﹤0.01% | 4380 |
|
|
2019
Q4 | $631K | Sell |
74,165
-6,384
| -8% | -$42.5K | ﹤0.01% | 4795 |
|
|
2019
Q3 | $398K | Buy |
80,549
+9,451
| +13% | +$50.6K | ﹤0.01% | 4795 |
|
|
2019
Q2 | $395K | Sell |
71,098
-666
| -0.9% | -$3.39K | ﹤0.01% | 4725 |
|
|
2019
Q1 | $362K | Buy |
71,764
+43,468
| +154% | +$276K | ﹤0.01% | 4744 |
|
|
2018
Q4 | $267K | Sell |
28,296
-2,517
| -8% | -$23.8K | ﹤0.01% | 5162 |
|
|
2018
Q3 | $247K | Buy |
30,813
+1,801
| +6% | +$18.1K | ﹤0.01% | 5352 |
|
|
2018
Q2 | $270K | Sell |
29,012
-33,158
| -53% | -$328K | ﹤0.01% | 5422 |
|
|
2018
Q1 | $643K | Buy |
62,170
+3,826
| +7% | +$46.5K | ﹤0.01% | 4849 |
|
|
2017
Q4 | $747K | Buy |
+58,344
| New | +$687K | ﹤0.01% | 4744 |
|
|
2017
Q2 | – | Sell |
-1,964
| Closed | -$20K | – | 6577 |
|
|
2017
Q1 | $20K | Sell |
1,964
-4,523
| -70% | -$55.5K | ﹤0.01% | 6086 |
|
|
2016
Q4 | $84K | Sell |
6,487
-6,336
| -49% | -$87.7K | ﹤0.01% | 5626 |
|
|
2016
Q3 | $211K | Buy |
+12,823
| New | +$222K | ﹤0.01% | 4992 |
|
Other funds holding ACIU
Morgan Stanley's ACIU Position: Q2 2026 in Review
Morgan Stanley increased its AC Immune (ACIU) stake by 48% in Q2 2026, buying an estimated $117K and bringing the position to 131,815 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #5760.
Morgan Stanley first reported a position in ACIU in Q3 2016 and has held it in 38 quarters since. The position peaked at $17.6M in Q4 2023. 40 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.
- Morgan Stanley held 131,815 shares of AC Immune worth $314K as of Q2 2026.
- Morgan Stanley bought 42,562 AC Immune shares in Q2 2026, an estimated $117K.
- AC Immune made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5760 holding.
- Morgan Stanley first reported a position in AC Immune in Q3 2016 and has held it in 38 quarters since.
- Morgan Stanley's AC Immune position peaked at $17.6M in Q4 2023.
- 40 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.